Baloxavir

Baloxavir (Baloxavir acid), derived from the proagent Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity[1][2].

Product Specifications

CAS Number

[1985605-59-1]

Product Name Alternative

Baloxavir acid; S-033447

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Influenza Virus

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Baloxavir.html

Concentration

10mM

Purity

99.75

Solubility

DMSO : 41.67 mg/mL (ultrasonic)

Smiles

O=C1N2[C@](COCC2)([H])N([C@@H]3C4=CC=CC=C4SCC5=C(F)C(F)=CC=C35)N6C1=C(O)C(C=C6)=O

Molecular Formula

C24H19F2N3O4S

Molecular Weight

483.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Omoto S, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018 Jun 25;8 (1) :9633.|[2]Noshi T, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018 Dec;160:109-117.